北京万泰生物药业股份有限公司 2025年第一季度报告

Core Viewpoint - The company, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., has reported its financial results for the first quarter of 2025, including significant impairment provisions for assets and receivables due to credit risks associated with its vaccine sales to local disease control centers [6][8]. Financial Data Summary - The financial statements for the first quarter of 2025 have not been audited [3]. - The company reported a total credit impairment loss of 45.8281 million yuan for accounts receivable due to increased payment delays from local disease control centers [6]. - Additionally, the company recognized a loss of 5.4978 million yuan for inventory write-downs based on accounting standards [7]. - The total impairment provisions for the first quarter amounted to 51.3259 million yuan, impacting the consolidated profit for the quarter by the same amount [8]. Governance and Compliance - The board of directors and senior management have confirmed the accuracy and completeness of the quarterly report, taking legal responsibility for its content [2][10]. - The supervisory board has approved the first quarter report, affirming that the report complies with relevant laws and regulations [12].